We will be comparing the differences between EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) and Nabriva Therapeutics plc (NASDAQ:NBRV) as far as risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EyePoint Pharmaceuticals Inc.	3.06M	72.27	80.31M	-1.35	0.00
Nabriva Therapeutics plc	9.98M	15.64	106.22M	-2.31	0.00

Demonstrates EyePoint Pharmaceuticals Inc. and Nabriva Therapeutics plc earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides us EyePoint Pharmaceuticals Inc. and Nabriva Therapeutics plc’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
EyePoint Pharmaceuticals Inc.	-2,624.51%	-414.6%	-142.9%
Nabriva Therapeutics plc	-1,064.33%	-124.4%	-107.4%

Risk & Volatility

A 2.02 beta means EyePoint Pharmaceuticals Inc.’s volatility is 102.00% more than S&P 500’s volatility. Competitively, Nabriva Therapeutics plc is 131.00% more volatile than S&P 500, because of the 2.31 beta.

Liquidity

2.6 and 2.6 are the respective Current Ratio and a Quick Ratio of EyePoint Pharmaceuticals Inc. Its rival Nabriva Therapeutics plc’s Current and Quick Ratios are 7.3 and 7.3 respectively. Nabriva Therapeutics plc has a better chance of clearing its pay short and long-term debts than EyePoint Pharmaceuticals Inc.

Insider and Institutional Ownership

EyePoint Pharmaceuticals Inc. and Nabriva Therapeutics plc has shares owned by institutional investors as follows: 62.3% and 58%. About 0.5% of EyePoint Pharmaceuticals Inc.’s share are owned by insiders. Insiders Comparatively, owned 0.1% of Nabriva Therapeutics plc shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
EyePoint Pharmaceuticals Inc.	-2.21%	21%	28.64%	25%	150%	40.21%
Nabriva Therapeutics plc	5.45%	12.11%	9.79%	-18.08%	-60.92%	45.89%

For the past year EyePoint Pharmaceuticals Inc. has weaker performance than Nabriva Therapeutics plc

Summary

On 7 of the 10 factors Nabriva Therapeutics plc beats EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis. Its lead product candidate is Durasert, (fluocinolone acetonide intravitreal implant), a micro-insert for the treatment of non-infectious uveitis affecting the posterior segment of the eye. In addition, the company's pre-clinical development program focuses on using its core Durasert platform technology to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. It has license agreements with Bausch and Lomb for Retisert product; a license agreement with Alimera for ocular applications of the ILUVIEN device; and a collaboration agreement with Pfizer for the Durasert device delivering latanoprost. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Watertown, Massachusetts.

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.